Assessing Toxicity in Drug Trials in Liver Disease

Abstract

Since the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver injury in clinical trials of new drugs is crucial. This review will focus on the systems that are used to assess drug-induced liver injury in clinical trials and will discuss how some of these criteria are inappropriate or inaccurate in this function together with suggestions for improvement.

Keywords

clinical trials - drug-induced liver injury - adverse event

Publikationsverlauf

Artikel online veröffentlicht:
08. März 2021

• References

• 1 Regev A. Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 2014; 34 (02) 227-239
• 2 McKenzie R, Fried MW, Sallie R. et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333 (17) 1099-1105
• 3 Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25 (10) 1135-1151
• 4 Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology 2020; 72 (01) 315-329
• 5 Rooks JB, Ory HW, Ishak KG. et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242 (07) 644-648
• 6 Hayashi PH. Overview of causality assessment in drug-induced liver injury. Clin Liver Dis (Hoboken) 2017; 9 (02) 29-33
• 7 Rockey DC, Seeff LB, Rochon J. et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-UCLAF causality assessment method. Hepatology 2010; 51 (06) 2117-2126
• 8 United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER): Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Final, July 2009.
• 9 National Cancer Institute Division of Cancer Treatment and Diagnosis. Cancer Therapy Evaluation Program. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . Accessed December 16, 2020
• 10 International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). www.MedDRA.org. Accessed December 16, 2020
• 11 Council for International Organizations of Medical Sciences. https://cioms.ch/wp-content/uploads/2017/01/Mgment_Safety_Info.pdf. Accessed December 16, 2020
• 12 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
• 13 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47 (01) 207-214
• 14 De Martin E, Michot JM, Papouin B. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018; 68 (06) 1181-1190